Press coverage about PTC Therapeutics (NASDAQ:PTCT) has trended somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. PTC Therapeutics earned a coverage optimism score of 0.16 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 44.5355838775904 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Spark Investment Management LLC Acquires 320,200 Shares of PTC Therapeutics, Inc. (PTCT) (americanbankingnews.com)
- American Century Companies Inc. Lowers Position in PTC Therapeutics, Inc. (PTCT) (americanbankingnews.com)
- PTC Therapeutics, Inc. (PTCT) Receives Average Rating of “Hold” from Analysts (americanbankingnews.com)
- Pinnacle Associates Ltd. Lowers Holdings in PTC Therapeutics, Inc. (PTCT) (americanbankingnews.com)
- PTC Therapeutics, Inc. (PTCT) Expected to Announce Quarterly Sales of $71.14 Million (americanbankingnews.com)
Several research analysts have recently commented on PTCT shares. Zacks Investment Research upgraded PTC Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 price objective on the stock in a report on Thursday, January 4th. Citigroup lifted their price objective on PTC Therapeutics from $24.00 to $35.00 and gave the stock a “buy” rating in a report on Wednesday, February 21st. JPMorgan Chase & Co. upgraded PTC Therapeutics from an “underweight” rating to a “neutral” rating and set a $15.00 price objective on the stock in a report on Thursday, November 16th. ValuEngine downgraded PTC Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, December 29th. Finally, Royal Bank of Canada started coverage on PTC Therapeutics in a report on Monday, January 29th. They issued a “sector perform” rating on the stock. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $20.57.
In related news, CEO Stuart Walter Peltz sold 2,230 shares of the business’s stock in a transaction dated Friday, January 5th. The stock was sold at an average price of $18.03, for a total transaction of $40,206.90. Following the transaction, the chief executive officer now owns 26,646 shares in the company, valued at approximately $480,427.38. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last 90 days, insiders have sold 2,719 shares of company stock worth $48,848. 8.10% of the stock is owned by company insiders.
COPYRIGHT VIOLATION NOTICE: “PTC Therapeutics (PTCT) Receives Media Sentiment Score of 0.16” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this news story on another domain, it was illegally copied and reposted in violation of U.S. and international copyright law. The legal version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3222470/ptc-therapeutics-ptct-receives-media-sentiment-score-of-0-16.html.
About PTC Therapeutics
PTC Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation.
Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.